Trial Profile
A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs RBX 2660 (Primary)
- Indications Clostridium difficile infections
- Focus Therapeutic Use
- Acronyms PUNCHCD2
- Sponsors Rebiotix
- 11 Jul 2023 According to a Ferring Pharmaceuticals media release, the integrated safety analysis of three phase 2 trials (PUNCH CD, PUNCH CD2, PUNCH Open-Label) and two phase 3(PUNCH CD3, PUNCH CD3-OLS) in Therapeutic Advances in Gastroenterology.
- 11 Jul 2023 Results presented in the Ferring Pharmaceuticals Media Release.
- 12 Dec 2022 Results assessing safety and efficacy of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection published in the Infectious Diseases and Therapy